Compare Abbott Laboratories (ABT) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MINISO Group Holding Ltd — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while MINISO Group Holding Ltd trades at $11.84 (market cap $3.52B). The key difference: Abbott Laboratories is far larger — about 47.4× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.69%). Which is the better fit depends on your goals.
| ABT | MNSO | |
|---|---|---|
Market Cap | $166.94B | $3.52B |
Sector | Health | Technology |
52-Week High | $136.62 | $26.63 |
52-Week Low | $82.57 | $11.30 |
Enterprise Value | $193.69B | $4.19B |
Dividend Yield | 2.63% | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MNSO trades at $11.90, up 1.54% today, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth of 28.5% year-over-year, and announced a HK$2 billion share repurchase program on June 29, 2026. Valuation ratios appear reasonable with a P/E of 12.11 and P/S of 1.1, while profitability metrics show a net income margin of 8.98% and ROE of 18.88%.
The outlook is cautiously optimistic given earnings momentum and shareholder-friendly actions, but risks include margin pressure from rising expenses and competitive threats. Analyst sentiment is positive with 75% buy ratings, though technical indicators suggest near-term resistance. Investors should weigh solid fundamentals against bearish price trends for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
